Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.

Veal GJ, Cole M, Chinnaswamy G, Sludden J, Jamieson D, Errington J, Malik G, Hill CR, Chamberlain T, Boddy AV.

Eur J Cancer. 2016 Mar;55:56-64. doi: 10.1016/j.ejca.2015.12.007. Epub 2016 Jan 12.

2.

Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma.

Yule SM, Price L, McMahon AD, Pearson AD, Boddy AV.

Clin Cancer Res. 2004 Jan 15;10(2):455-60.

3.

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.

Xie H, Griskevicius L, Ståhle L, Hassan Z, Yasar U, Rane A, Broberg U, Kimby E, Hassan M.

Eur J Pharm Sci. 2006 Jan;27(1):54-61. Epub 2005 Sep 23.

PMID:
16183265
4.

Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.

Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD.

Pharmacogenet Genomics. 2008 Jun;18(6):515-23. doi: 10.1097/FPC.0b013e3282fc9766.

PMID:
18496131
5.

Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma.

Shu W, Chen L, Hu X, Zhang M, Chen W, Ma L, Liu X, Huang J, Pang T, Li J, Zhang Y.

J Clin Pharmacol. 2017 Jul;57(7):886-898. doi: 10.1002/jcph.878. Epub 2017 Feb 9.

PMID:
28181240
6.

Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy.

Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M.

Eur J Cancer. 2011 Jul;47(10):1556-63. doi: 10.1016/j.ejca.2011.03.008. Epub 2011 Apr 7.

PMID:
21482104
7.

Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.

Nakajima M, Komagata S, Fujiki Y, Kanada Y, Ebi H, Itoh K, Mukai H, Yokoi T, Minami H.

Pharmacogenet Genomics. 2007 Jun;17(6):431-45.

PMID:
17502835
8.

Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil.

Jamieson D, Lee J, Cresti N, Jackson R, Griffin M, Sludden J, Verrill M, Boddy AV.

Cancer Chemother Pharmacol. 2014 Oct;74(4):667-74. doi: 10.1007/s00280-014-2541-6. Epub 2014 Jul 24.

PMID:
25055937
9.

Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.

Hill CR, Cole M, Errington J, Malik G, Boddy AV, Veal GJ.

Clin Pharmacokinet. 2014 Aug;53(8):741-51. doi: 10.1007/s40262-014-0153-2.

10.

Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.

Shu W, Guan S, Yang X, Liang L, Li J, Chen Z, Zhang Y, Chen L, Wang X, Huang M.

Br J Clin Pharmacol. 2016 Feb;81(2):327-40. doi: 10.1111/bcp.12800. Epub 2015 Dec 25.

12.

Cyclophosphamide pharmacokinetics in children.

Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson AD, Idle JR.

Br J Clin Pharmacol. 1996 Jan;41(1):13-19.

13.

Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for Lymphoma.

Bachanova V, Shanley R, Malik F, Chauhan L, Lamba V, Weisdorf DJ, Burns LJ, Lamba JK.

Biol Blood Marrow Transplant. 2015 May;21(5):944-8. doi: 10.1016/j.bbmt.2015.02.001. Epub 2015 Feb 10.

14.

Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Bittner S, Schmalenberg H, Schmits R, Pfreundschuh M, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).

Ann Oncol. 2003 Jun;14(6):881-93.

PMID:
12796026
15.

Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.

Attarbaschi A, Mann G, Dworzak M, Trebo M, Urban C, Fink FM, Horcher E, Reiter A, Riehm H, Gadner H; Austrian Cooperative Study Group.

Wien Klin Wochenschr. 2002 Dec 30;114(23-24):978-86.

PMID:
12635465
16.

Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol.

Atra A, Imeson JD, Hobson R, Gerrard M, Hann IM, Eden OB, Carter RL, Pinkerton CR.

Br J Cancer. 2000 Apr;82(8):1396-402.

17.

B cell non-Hodgkin's lymphoma: experience from a tertiary care cancer center.

Prakash G, Sharma A, Raina V, Kumar L, Sharma MC, Mohanti BK.

Ann Hematol. 2012 Oct;91(10):1603-11. doi: 10.1007/s00277-012-1491-5. Epub 2012 May 15.

PMID:
22584851
18.

Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.

Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F.

Blood. 2002 Apr 15;99(8):2685-93.

19.

Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.

Su HI, Sammel MD, Velders L, Horn M, Stankiewicz C, Matro J, Gracia CR, Green J, DeMichele A.

Fertil Steril. 2010 Jul;94(2):645-54. doi: 10.1016/j.fertnstert.2009.03.034. Epub 2009 Apr 18.

20.

The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.

Helsby NA, Hui CY, Goldthorpe MA, Coller JK, Soh MC, Gow PJ, De Zoysa JZ, Tingle MD.

Br J Clin Pharmacol. 2010 Dec;70(6):844-53. doi: 10.1111/j.1365-2125.2010.03789.x.

Supplemental Content

Support Center